Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Jain, P, Finger, PT, Fili, M, Damato, B, Coupland, SE, Heimann, H, Kenawy, N, J Brouwer, N, Marinkovic, M, Van Duinen, SG, Caujolle, JP, Maschi, C, Seregard, S, Pelayes, D, Folgar, M, Yousef, YA, Krema, H, Gallie, B, Calle-Vasquez, A, American Joint Committee on Cancer Ophthalmic Oncology Task Force & Heegaard, S 2021, 'Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study', The British journal of ophthalmology, vol. 105, no. 10, pp. 1358-1364. https://doi.org/10.1136/bjophthalmol-2020-316293

APA

Jain, P., Finger, P. T., Fili, M., Damato, B., Coupland, S. E., Heimann, H., Kenawy, N., J Brouwer, N., Marinkovic, M., Van Duinen, S. G., Caujolle, J. P., Maschi, C., Seregard, S., Pelayes, D., Folgar, M., Yousef, Y. A., Krema, H., Gallie, B., Calle-Vasquez, A., ... Heegaard, S. (2021). Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study. The British journal of ophthalmology, 105(10), 1358-1364. https://doi.org/10.1136/bjophthalmol-2020-316293

CBE

Jain P, Finger PT, Fili M, Damato B, Coupland SE, Heimann H, Kenawy N, J Brouwer N, Marinkovic M, Van Duinen SG, Caujolle JP, Maschi C, Seregard S, Pelayes D, Folgar M, Yousef YA, Krema H, Gallie B, Calle-Vasquez A, American Joint Committee on Cancer Ophthalmic Oncology Task Force, Heegaard S. 2021. Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study. The British journal of ophthalmology. 105(10):1358-1364. https://doi.org/10.1136/bjophthalmol-2020-316293

MLA

Vancouver

Author

Jain, Puneet ; Finger, Paul T ; Fili, Maria ; Damato, Bertil ; Coupland, Sarah E ; Heimann, Heinrich ; Kenawy, Nihal ; J Brouwer, Niels ; Marinkovic, Marina ; Van Duinen, Sjoerd G ; Caujolle, Jean Pierre ; Maschi, Celia ; Seregard, Stefan ; Pelayes, David ; Folgar, Martin ; Yousef, Yacoub A ; Krema, Hatem ; Gallie, Brenda ; Calle-Vasquez, Alberto ; American Joint Committee on Cancer Ophthalmic Oncology Task Force ; Heegaard, Steffen. / Conjunctival melanoma treatment outcomes in 288 patients : a multicentre international data-sharing study. In: The British journal of ophthalmology. 2021 ; Vol. 105, No. 10. pp. 1358-1364.

Bibtex

@article{a6930131d00748e08bb3331c1ea4f61f,
title = "Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study",
abstract = "BACKGROUND: To relate conjunctival melanoma characteristics to local control.METHODS: Retrospective, registry-based interventional study with data gathered from 10 ophthalmic oncology centres from 9 countries on 4 continents. Conjunctival melanoma patients diagnosed between January 2001 and December 2013 were enrolled in the study. Primary treatments included local excision, excision with cryotherapy and exenteration. Adjuvant treatments included topical chemotherapy, brachytherapy, proton and external beam radiotherapy (EBRT). Cumulative 5-year and 10-year Kaplan-Meier local recurrence rates were related to clinical and pathological T-categories of the eighth edition of the American Joint Committee on Cancer (AJCC) staging system.RESULTS: 288 patients had a mean initial age of 59.7±16.8 years. Clinical T-categories (cT) were cT1 (n=218,75.7%), cT2 (n=34, 11.8%), cT3 (n=15, 5.2%), cTx (n=21,7.3%) with no cT4. Primary treatment included local excision (n=161/288, 55.9%) followed by excision biopsy with cryotherapy (n=108/288, 37.5%) and exenteration (n=5/288, 1.7%). Adjuvant therapies included topical mitomycin (n=107/288, 37.1%), plaque-brachytherapy (n=55/288, 19.1%), proton-beam (n=36/288, 13.5%), topical interferon (n=20/288, 6.9%) and EBRT (n=15/288, 5.2%). Secondary exenteration was performed (n=11/283, 3.9%). Local recurrence was noted in 19.1% (median=3.6 years). Cumulative local recurrence was 5.4% (3.2-8.9%), 19.3% (14.4-25.5%) and 36.9% (26.5-49.9%) at 1, 5 and 10 years, respectively. cT3 and cT2 tumors were twice as likely to recur than cT1 tumours, but only cT3 had statistically significantly greater risk of local recurrence than T1 (p=0.013). Factors such as tumour ulceration, plica or caruncle involvement and tumour thickness were not significantly associated with an increased risk of local recurrence.CONCLUSION: This multicentre international study showed that eighth edition of AJCC tumour staging was related to the risk of local recurrence of conjunctival melanoma after treatment. The 10-year cumulative local recurrence remains high despite current management.",
author = "Puneet Jain and Finger, {Paul T} and Maria Fili and Bertil Damato and Coupland, {Sarah E} and Heinrich Heimann and Nihal Kenawy and {J Brouwer}, Niels and Marina Marinkovic and {Van Duinen}, {Sjoerd G} and Caujolle, {Jean Pierre} and Celia Maschi and Stefan Seregard and David Pelayes and Martin Folgar and Yousef, {Yacoub A} and Hatem Krema and Brenda Gallie and Alberto Calle-Vasquez and {American Joint Committee on Cancer Ophthalmic Oncology Task Force} and Steffen Heegaard",
note = "{\textcopyright} Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2021",
month = oct,
doi = "10.1136/bjophthalmol-2020-316293",
language = "English",
volume = "105",
pages = "1358--1364",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "B M J Group",
number = "10",

}

RIS

TY - JOUR

T1 - Conjunctival melanoma treatment outcomes in 288 patients

T2 - a multicentre international data-sharing study

AU - Jain, Puneet

AU - Finger, Paul T

AU - Fili, Maria

AU - Damato, Bertil

AU - Coupland, Sarah E

AU - Heimann, Heinrich

AU - Kenawy, Nihal

AU - J Brouwer, Niels

AU - Marinkovic, Marina

AU - Van Duinen, Sjoerd G

AU - Caujolle, Jean Pierre

AU - Maschi, Celia

AU - Seregard, Stefan

AU - Pelayes, David

AU - Folgar, Martin

AU - Yousef, Yacoub A

AU - Krema, Hatem

AU - Gallie, Brenda

AU - Calle-Vasquez, Alberto

AU - American Joint Committee on Cancer Ophthalmic Oncology Task Force

A2 - Heegaard, Steffen

N1 - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2021/10

Y1 - 2021/10

N2 - BACKGROUND: To relate conjunctival melanoma characteristics to local control.METHODS: Retrospective, registry-based interventional study with data gathered from 10 ophthalmic oncology centres from 9 countries on 4 continents. Conjunctival melanoma patients diagnosed between January 2001 and December 2013 were enrolled in the study. Primary treatments included local excision, excision with cryotherapy and exenteration. Adjuvant treatments included topical chemotherapy, brachytherapy, proton and external beam radiotherapy (EBRT). Cumulative 5-year and 10-year Kaplan-Meier local recurrence rates were related to clinical and pathological T-categories of the eighth edition of the American Joint Committee on Cancer (AJCC) staging system.RESULTS: 288 patients had a mean initial age of 59.7±16.8 years. Clinical T-categories (cT) were cT1 (n=218,75.7%), cT2 (n=34, 11.8%), cT3 (n=15, 5.2%), cTx (n=21,7.3%) with no cT4. Primary treatment included local excision (n=161/288, 55.9%) followed by excision biopsy with cryotherapy (n=108/288, 37.5%) and exenteration (n=5/288, 1.7%). Adjuvant therapies included topical mitomycin (n=107/288, 37.1%), plaque-brachytherapy (n=55/288, 19.1%), proton-beam (n=36/288, 13.5%), topical interferon (n=20/288, 6.9%) and EBRT (n=15/288, 5.2%). Secondary exenteration was performed (n=11/283, 3.9%). Local recurrence was noted in 19.1% (median=3.6 years). Cumulative local recurrence was 5.4% (3.2-8.9%), 19.3% (14.4-25.5%) and 36.9% (26.5-49.9%) at 1, 5 and 10 years, respectively. cT3 and cT2 tumors were twice as likely to recur than cT1 tumours, but only cT3 had statistically significantly greater risk of local recurrence than T1 (p=0.013). Factors such as tumour ulceration, plica or caruncle involvement and tumour thickness were not significantly associated with an increased risk of local recurrence.CONCLUSION: This multicentre international study showed that eighth edition of AJCC tumour staging was related to the risk of local recurrence of conjunctival melanoma after treatment. The 10-year cumulative local recurrence remains high despite current management.

AB - BACKGROUND: To relate conjunctival melanoma characteristics to local control.METHODS: Retrospective, registry-based interventional study with data gathered from 10 ophthalmic oncology centres from 9 countries on 4 continents. Conjunctival melanoma patients diagnosed between January 2001 and December 2013 were enrolled in the study. Primary treatments included local excision, excision with cryotherapy and exenteration. Adjuvant treatments included topical chemotherapy, brachytherapy, proton and external beam radiotherapy (EBRT). Cumulative 5-year and 10-year Kaplan-Meier local recurrence rates were related to clinical and pathological T-categories of the eighth edition of the American Joint Committee on Cancer (AJCC) staging system.RESULTS: 288 patients had a mean initial age of 59.7±16.8 years. Clinical T-categories (cT) were cT1 (n=218,75.7%), cT2 (n=34, 11.8%), cT3 (n=15, 5.2%), cTx (n=21,7.3%) with no cT4. Primary treatment included local excision (n=161/288, 55.9%) followed by excision biopsy with cryotherapy (n=108/288, 37.5%) and exenteration (n=5/288, 1.7%). Adjuvant therapies included topical mitomycin (n=107/288, 37.1%), plaque-brachytherapy (n=55/288, 19.1%), proton-beam (n=36/288, 13.5%), topical interferon (n=20/288, 6.9%) and EBRT (n=15/288, 5.2%). Secondary exenteration was performed (n=11/283, 3.9%). Local recurrence was noted in 19.1% (median=3.6 years). Cumulative local recurrence was 5.4% (3.2-8.9%), 19.3% (14.4-25.5%) and 36.9% (26.5-49.9%) at 1, 5 and 10 years, respectively. cT3 and cT2 tumors were twice as likely to recur than cT1 tumours, but only cT3 had statistically significantly greater risk of local recurrence than T1 (p=0.013). Factors such as tumour ulceration, plica or caruncle involvement and tumour thickness were not significantly associated with an increased risk of local recurrence.CONCLUSION: This multicentre international study showed that eighth edition of AJCC tumour staging was related to the risk of local recurrence of conjunctival melanoma after treatment. The 10-year cumulative local recurrence remains high despite current management.

UR - http://www.scopus.com/inward/record.url?scp=85108078941&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2020-316293

DO - 10.1136/bjophthalmol-2020-316293

M3 - Journal article

C2 - 32892167

VL - 105

SP - 1358

EP - 1364

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 10

ER -

ID: 61988194